EN DE

Dalian BIO-CHEM Company (603360) Fair Value & Analysis

Basic Materials · CN · Market cap 13.4B CNY

DB Dalian BIO-CHEM Company 603360 · SHG
Price¥13.87
Fair Value¥5.05
Upside-63.6%
Quality69/100
Watch Dalian BIO-CHEM Company for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Solidly profitable · 11.5% net margin
Moderate debt · generates free cash flow
Trails peers (5/13)
Moderate moat 51/100
Evidence: Medium Range ¥3.79 – ¥6.31 Share as image

Fair value as of: Jul 11, 2026

From 26 valuation models · updated 30 days ago

Share price −3.1% over the past month.

A solid business, but screening 64% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (¥6.31). The favourable scenario is already priced in.
  • Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

¥38.13 ¥3.55 Fair Value ¥5.05 Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.

How to read this chart

60‑month range ¥3.55 – ¥38.13 · fair‑value band ¥3.79 – ¥6.31 · the ¥13.87 price screens above the ¥5.05 fair value. Dashed = 300-day average. As of Jul 11, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Dalian BIO-CHEM Company (603360) currently trades at ¥13.87, while our model-based Fair Value estimate is ¥5.05, implying the stock looks roughly 63.6% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Dalian BIO-CHEM Company generated revenue of 1.5B CNY at a net margin of 11.5%. Revenue declined 46.1% year over year. It earns a return on equity of 11.0%. The balance sheet holds a net cash position of 136M CNY. Fundamentals as of Jul 11, 2026

Our scenario range runs from ¥3.79 (bear case) to ¥6.31 (bull case); at ¥13.87, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 64% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -64%, 603360 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF ¥11.28 ¥21.82 ¥41.69 80
Residual Income ¥1.98 ¥2.44 ¥4.82 76
Rev-Margin DCF ¥5.66 ¥9.13 ¥14.22 74
All 26 models by family
DCF Models
FCF DCF ¥11.77 ¥19.68 ¥41.88 38
Owner Earnings ¥6.53 ¥14.00 ¥29.53 31
5Y Revenue Exit ¥5.66 ¥8.67 ¥14.03 39
5Y EBITDA Exit ¥7.21 ¥12.06 ¥20.38 41
5Y P/E Exit ¥6.38 ¥10.90 ¥16.43 38
10Y Revenue Exit ¥7.35 ¥11.78 ¥16.66 36
10Y EBITDA Exit ¥8.54 ¥14.68 ¥25.13 37
10Y P/E Exit ¥7.96 ¥13.14 ¥21.35 35
Earnings-Based
Graham-Dodd ¥2.02 ¥13.84 ¥19.41 54
Lynch FV ¥4.07 ¥5.82 ¥7.56 50
PEG = 1.0 ¥4.07 ¥5.82 ¥7.56 46
EPV ¥4.78 ¥5.49 ¥6.10 59
Dividend Discount
Gordon GGM ¥4.31 ¥8.96 ¥14.22 70
DDM Multi-Stage ¥4.31 ¥7.56 ¥9.41 61
Multiples
P/E Multiple ¥3.79 ¥5.05 ¥6.31 63
P/S Multiple ¥2.75 ¥3.66 ¥4.58 58
P/B Multiple ¥3.79 ¥5.05 ¥6.31 55
EV/EBIT ¥6.04 ¥7.87 ¥9.70 53
EV/EBITDA ¥5.52 ¥7.17 ¥8.83 54
EV/Revenue ¥3.11 ¥4.21 ¥5.31 43
Asset-Based
NCAV (Graham) ¥0.9800 ¥1.32 ¥1.97 50
Growth DCF
Growth DCF ¥11.28 ¥21.82 ¥41.69 80
Rev-Margin DCF ¥5.66 ¥9.13 ¥14.22 74
Economic Profit
Residual Income ¥1.98 ¥2.44 ¥4.82 76
ROIC Compounder ¥5.70 ¥7.82 ¥10.69 72
Growth Earnings
Growth-Adj P/E ¥5.14 ¥7.35 ¥9.55 68

Widest divergence: DCF Models (¥12.06) versus Asset-Based (¥1.32). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) 1.5B CNY
Revenue growth (YoY) -46.1%
Net margin 11.5%
Return on equity 11.0%
Free cash flow 510M CNY FY2025
P/E ratio 75.6
More key figures
Operating margin 11.1%
EPS (TTM) ¥0.2500
EPS growth (YoY) -62.5%
Net cash 136M CNY FY2024

Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 69/100

Of which business quality 70 · Market factors (momentum, volatility) 18

Profitability 42
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 99
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 66
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 8
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Dalian BIO-CHEM Company Limited researches, develops, produces, and sells industrial fungicides in China and internationally. It offers various isothiazolinone fungicides, including CMIT/MIT, MIT, OIT, DCOIT, and BIT series products; and OEM/ODM services. The company was founded in 2003 and is headquartered in Dalian, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Dalian BIO-CHEM Company reported revenue of ¥1.7B in FY2025 versus ¥1.0B in FY2021, a compound +14.4%/yr. Reported net income was ¥210M in FY2025, compounding −4.3%/yr from FY2021.

Growth Quality 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
1.7B CNY
Latest YoY
+31.4%
Avg. growth/yr (3Y)
+11.1%
Avg. growth/yr (5Y)
+18.1%
Avg. growth/yr (14Y)
+16.3%
Revenue +14.4%/yr
FY21 ¥1.0B
FY22 ¥1.3B
FY23 ¥1.1B
FY24 ¥1.3B
FY25 ¥1.7B
Net income −4.3%/yr
FY21 ¥250M
FY22 ¥403M
FY23 ¥328M
FY24 ¥345M
FY25 ¥210M

603360 screens 64% overvalued. Compare with Linde plc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Dalian BIO-CHEM Company Fair Value". https://www.fairvalue-calculator.com/stock/603360

Peer Group

Specialty Chemicals · 676 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 69 · Top 25%
Fair Value upside −64% · Bottom 25%
Return on equity (TTM) 11% · Above median
Return on assets 5% · Above median
Net margin (TTM) 12% · Top 25%
Operating margin (TTM) 11% · Above median
Revenue growth -46% · Bottom 25%
Debt / equity 0.56× · Higher than 75% of peers

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

P/E (TTM) 75.6× · Pricier than 75% of peers
P/B 9.62× · Pricier than 75% of peers
P/S (TTM) 8.91× · Pricier than 75% of peers
P/FCF 3.9× · Pricier than median
EV/EBITDA 31.9× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 0 · sector 19
PAST 44 · sector 23
HEALTH 72 · sector 95
DIVIDEND 0 · sector 25

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $489.98 $222.03 -55%
Nan Ya Plastics Corporation 1303 181.50 TWD 255.83 TWD +41%
Wanhua Chemical Group 600309 ¥70.04 ¥68.03 -3%
Novozymes A/S NSISB kr 428.20 kr 179.66 -58%
Asian Paints Limited ASIANPAINT ₹2,689 ₹668.81 -75%
Solar Industries India Limited SOLARINDS ₹18,236 ₹2,793 -85%
Pidilite Industries Limited PIDILITIND ₹1,560 ₹351.84 -77%
PT Chandra Asri Pacific Tbk TPIA 1,805 IDR 2,888 IDR +60%
Linde India Limited LINDEINDIA ₹7,115 ₹757.93 -89%
Berger Paints India Limited BERGEPAINT ₹493.70 ₹164.29 -67%

Compare Dalian BIO-CHEM Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Dalian BIO-CHEM Company (603360) overvalued or undervalued?
As of Jul 11, 2026, our model estimates a fair value of ¥5.05 versus a price of ¥13.87, about −64% (overvalued).
What is the fair value of 603360?
Our model-based fair value for Dalian BIO-CHEM Company is ¥5.05 (as of Jul 11, 2026), built from audited fundamentals. The current price is ¥13.87.
What is the quality score of 603360?
Dalian BIO-CHEM Company has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Dalian BIO-CHEM Company (603360)?
Dalian BIO-CHEM Company reported trailing-twelve-month revenue of about 1.5B CNY (latest available figure, as of Jul 11, 2026).
What is the net profit margin of 603360?
The net profit margin of Dalian BIO-CHEM Company is about 11.5%, meaning it keeps roughly 11.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Dalian BIO-CHEM Company and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.